Reading Time: 4 mins Key Opinion Leaders (KOLs) offer invaluable benefits to pharmaceutical companies in developing new treatments or drugs. They provide intellectual and academic guidance during clinical trials, vastly improving success rates. To know more, check out our […]
KOL Mapping vs KOL Identification: Unraveling the Contrasts Read More »
Reading Time: 6 mins Before we even begin, let me bust a fundamental myth. KOLS ARE NOT INFLUENCERS!!! A Key Opinion Leader (KOL) is an individual widely acknowledged for their expertise and experience, both in online and offline spheres.
What is a KOL in Pharma and How to Identify Them? Read More »
Reading Time: 4 mins The cost to develop and launch a new drug in the market can be, by some estimates, as staggeringly high as $4.54 Bn. It is also remarkably tedious, sometimes taking up to 15 years to
Automated Cell Counting: The Ultimate Drug Development Accelerator Read More »
Reading Time: 4 mins Note: This is the 2nd article in the 5-part “Supply Chain Data Strategy” series, an initiative to aware supply chain leaders about the power of data-driven decision making. Recap: In our previous article (1st part)
Why Do You Need Supply Chain Data Strategy? A Multiple Scenario-wise Explanation Read More »
Reading Time: 6 mins Against a backdrop of increased climate commitments by governments and businesses and the visible costs of the climate emergency, regulations calling for more granular monitoring of climate-related data and transition plans of companies are hardly
The Rising Tide of Climate-Related Data Read More »